Vizient has awarded Cresilon an Innovative Technology contract for its hemostatic gel, TRAUMAGEL. PR Newswire has the release.
The contract was awarded based on review from “hospital experts who serve on one of Vizient's client-led councils, and it signifies to Vizient clients its unique qualities that potentially bring improvement to the healthcare industry.”
TRAUMAGEL is a “gel in a syringe for traumatic hemorrhage and the only flowable hemostatic with U.S. FDA 510(k) clearance for temporary external use to control moderate to severe bleeding. TRAUMAGEL is supplied in a 30 mL sterile prefilled syringe, requires no preparation, is easy to apply and remove, stops bleeding rapidly, and provides immediate hemorrhage control.”
Vizient uses its Innovative Technology Platform to work with “client-led councils and task forces to evaluate products for their potential to bring real innovation to healthcare. If it is determined that a product is innovative, Vizient may award a contract outside of the competitive bid cycle.”
